Molecular Cancer Therapeutics : Impact Factor & More
eISSN: 1538-8514pISSN: 1535-7163
Share this on:
Key Metrics
CiteScore 
10.2
H-Index
190
Impact Factor
5 - 10
SJR
Q1Oncology
SNIP
1.21
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Molecular Cancer Therapeutics
Molecular Cancer Therapeutics Journal Specifications
| Overview | |
| Publisher | AMER ASSOC CANCER RESEARCH |
| Language | English |
| Frequency | Monthly |
| General Details |
View less
Planning to publish in Molecular Cancer Therapeutics ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Molecular Cancer Therapeutics
Enhanced Antitumor Efficacy of Combined PTC596 and PD1 Blockade in Hepatocellular Carcinoma.
- 19 May 2026
- Molecular cancer therapeutics
Synthetic Inducible Bacteria Normalize the Microenvironment of Refractory Tumors, Potentiating Checkpoint Inhibitor Responses.
- 18 May 2026
- Molecular cancer therapeutics
Dual inhibition of PARP and ATR induces synthetic lethal vulnerability in prostate cancer with CDK12 deficiency.
- 14 May 2026
- Molecular cancer therapeutics
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations.
- 13 May 2026
- Molecular cancer therapeutics
A Bispecific Anti-Fluorescein × Anti-CD3 T-cell Engager in Combination with Fluoresceinated Adaptors Enables Lysis of AML Cells.
- 12 May 2026
- Molecular cancer therapeutics
Tri-specific Humabody CB307 Targeting CD137, Prostate-specific Membrane Antigen, and Human Serum Albumin Whole-body Biodistribution Measured with 89Zr-CB307 PET.
- 7 May 2026
- Molecular cancer therapeutics
Enhanced Antitumor Efficacy of Combined PTC596 and PD1 Blockade in Hepatocellular Carcinoma.
- 19 May 2026
- Molecular cancer therapeutics
Synthetic Inducible Bacteria Normalize the Microenvironment of Refractory Tumors, Potentiating Checkpoint Inhibitor Responses.
- 18 May 2026
- Molecular cancer therapeutics
Dual inhibition of PARP and ATR induces synthetic lethal vulnerability in prostate cancer with CDK12 deficiency.
- 14 May 2026
- Molecular cancer therapeutics
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations.
- 13 May 2026
- Molecular cancer therapeutics
A Bispecific Anti-Fluorescein × Anti-CD3 T-cell Engager in Combination with Fluoresceinated Adaptors Enables Lysis of AML Cells.
- 12 May 2026
- Molecular cancer therapeutics
Tri-specific Humabody CB307 Targeting CD137, Prostate-specific Membrane Antigen, and Human Serum Albumin Whole-body Biodistribution Measured with 89Zr-CB307 PET.
- 7 May 2026
- Molecular cancer therapeutics
FAQs on Molecular Cancer Therapeutics
How long has Molecular Cancer Therapeutics been actively publishing? 
What is the publishing frequency of Molecular Cancer Therapeutics?
How many articles did Molecular Cancer Therapeutics publish last year?
What is the eISSN & pISSN for Molecular Cancer Therapeutics?
What is Citescore for Molecular Cancer Therapeutics?
What is the H Index for Molecular Cancer Therapeutics ?
What is SNIP score for Molecular Cancer Therapeutics?
What is the SJR for Molecular Cancer Therapeutics?
Who is the publisher of Molecular Cancer Therapeutics?
